Adicet Bio (ACET) CEO granted 468,555 stock options at $6.81 strike

Rhea-AI Filing Summary

Adicet Bio, Inc. reported that President & CEO Chen Schor received a grant of stock options representing the right to buy 468,555 shares of common stock. The options have an exercise price of $6.81 per share and expire on March 24, 2036.

This award is compensation-related and not an open-market share purchase or sale. The filing notes that one forty-eighth of the options vest each month over 48 months from the grant date, contingent on Mr. Schor continuing his service with the company.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Schor Chen

Role President & CEO

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	468,555	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 468,555 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Schor Chen

(Last) (First) (Middle)

C/O ADICET BIO, INC.

131 DARTMOUTH STREET, FLOOR 3

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Adicet Bio, Inc. [ ACET ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$6.81	03/25/2026		A		468,555		(1)	03/24/2036	Common Stock	468,555	$0.00	468,555	D

Explanation of Responses:

1. (1) 1/48th of the shares shall vest on each of the next forty-eight (48) monthly anniversaries of the grant date, provided that the Reporting Person maintains a service relationship with the Issuer as of the applicable vesting dates.

	/s/ Nick Harvey, Attorney-in-Fact	03/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Adicet Bio (ACET) disclose for Chen Schor?

Adicet Bio disclosed that President & CEO Chen Schor received a grant of stock options for 468,555 shares of common stock as compensation. These options were awarded at an exercise price of $6.81 per share and are not an open-market share purchase.

How many Adicet Bio (ACET) options were granted to the CEO and at what price?

Chen Schor was granted stock options covering 468,555 shares of Adicet Bio common stock at an exercise price of $6.81 per share. This award increases his potential equity exposure without an immediate cash outlay or open-market transaction.

What is the vesting schedule for Chen Schor’s Adicet Bio (ACET) option grant?

The option grant vests in equal monthly installments over four years. Specifically, one forty-eighth of the 468,555 options vests on each monthly anniversary of the grant date, provided Chen Schor maintains a service relationship with Adicet Bio on each vesting date.

When do Chen Schor’s Adicet Bio (ACET) stock options expire?

The reported stock options granted to Chen Schor expire on March 24, 2036. If unexercised by that expiration date, the options will lapse. The long-dated term gives significant time for potential future exercise, subject to vesting and continued service conditions.

Did Chen Schor buy or sell Adicet Bio (ACET) shares in the market?

The filing shows a grant of stock options as compensation, not a market trade. Chen Schor did not report buying or selling common shares in the open market; instead he received options with a $6.81 exercise price that may be exercised in the future.